{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-302150","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.084020+00:00","generated_at":"2026-06-07T08:36:00.001180+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mylan files ANDA for generic APONVIE; Heron to defend 10 patents","bullets":["Mylan filed paragraph IV certification notice for generic version of APONVIE (aprepitant).","Heron will file patent infringement lawsuit within 45 days of December 18, 2023 notice.","10 Orange Book-listed patents expiring September 18, 2035 are challenged as invalid or not infringed.","FDA approval of Mylan's ANDA stayed for 7.5 years if suit is timely filed, absent court ruling."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-302150","json":"https://secwatch.observer/filing/0001193125-23-302150.json","markdown":"https://secwatch.observer/filing/0001193125-23-302150.md","text":"https://secwatch.observer/filing/0001193125-23-302150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312523302150/0001193125-23-302150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312523302150/d668785d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:36:00.001180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}